The extracellular signal-related kinases 1 and 2 (ERK1/2) are key proteins mediating mitogen-activated protein kinase signaling downstream of RAS: phosphorylation of ERK1/2 leads to nuclear uptake and modulation of multiple targets 1 . Here, we show that reduced dosage of ERF, which encodes an inhibitory ETS transcription factor directly bound by ERK1/2 (refs. 2-7), causes complex craniosynostosis (premature fusion of the cranial sutures) in humans and mice. Features of this newly recognized clinical disorder include multiple-suture synostosis, craniofacial dysmorphism, Chiari malformation and language delay. Mice with functional Erf levels reduced to ~30% of normal exhibit postnatal multiple-suture synostosis; by contrast, embryonic calvarial development appears mildly delayed. Using chromatin immunoprecipitation in mouse embryonic fibroblasts and high-throughput sequencing, we find that ERF binds preferentially to elements away from promoters that contain RUNX or AP-1 motifs. This work identifies ERF as a novel regulator of osteogenic stimulation by RAS-ERK signaling, potentially by competing with activating ETS factors in multifactor transcriptional complexes.
After excluding previously described variants and genomic regions for which the brothers did not share the maternal allele, 135 nonsynonymous sequence changes remained, including 5 nonsense mutations (Supplementary Table 1 ). One of the nonsense mutations (c.547C>T; p.Arg183*) was present in ERF, encoding an inhibitory ETS family transcription factor located on chromosome 19q13.2. ERF was previously shown to be a prominent binding target of the paralogous ERK1/2 kinases 7 , key effectors of the RAS-MEK-ERK signal transduction cascade; the transcriptional activity of ERF is primarily regulated by ERK1/2-mediated phosphorylation, which leads to its export from the nucleus 5, 6 . We considered ERF as a candidate because activation of ERK1/2 signaling was previously shown in craniosynostosis 9, 10 . We confirmed segregation of the mutation from the maternal grandmother to the two affected children (family 1; Supplementary Fig. 1) .
To analyze the possible contribution of ERF mutation to the pathological phenotype, we sequenced the gene in 411 samples from unrelated subjects with craniosynostosis ( Table 1 ) and 288 northern European controls. Heterozygous loss-of-function mutations were present in an additional 11 samples from affected individuals but were not identified in normal controls (P = 0.004, Fisher's exact test) ( Fig. 2 and Table 2 ). No deletions were identified in 276 mutation-negative samples. We analyzed earlier generations, finding 26 mutationpositive individuals in total (Supplementary Fig. 1 ). In 4 families, the mutation had arisen de novo from a parent (n = 2), grandparent (n = 1) or great-grandparent (n = 1) (Supplementary Fig. 2 ). The occurrence Reduced dosage of ERF causes complex craniosynostosis in humans and mice and links ERK1/2 signaling to regulation of osteogenesis l e t t e r s of mutations only in samples from affected individuals and the identification of multiple de novo cases establish that ERF mutations are the cause of craniosynostosis in these families.
ERF comprises 4 exons ( Fig. 2a) and encodes a ubiquitously expressed member of the ETS family of transcription factors (numbering 28 in humans) 11 , which acts as a negative transcriptional regulator, either by competing with other ETS family members for DNA binding or through interaction with unique targets 2, 3 . Functionally characterized motifs in ERF include the N-terminal DNA-binding (ETS), central ERK interaction and C-terminal repressor domains (Fig. 2b) ; DNA binding targets a core motif (5′-GGA(A/T)-3′), with little sequence discrimination from other ETS family members 12 . The identified ERF mutations were diverse: the three missense changes (one recurrent) were located in critical residues in the DNA-binding ETS domain or disrupted the initiation codon, whereas the remaining eight mutations comprised a splice-site mutation, two nonsense changes and three frameshift mutations (one recurrent, present in three families) (Fig. 2, Table 2 and Supplementary Fig. 3a) . Immunoblotting of fibroblasts or lymphoblastoid cells from affected individuals showed lower expression of full-length ERF associated with the initiation codon and nonsense mutations but not the missense substitutions affecting the ETS domain (Supplementary Fig. 3b ). DNA-binding domain alterations did not repress transcription from ETS binding site-containing promoters (Supplementary Fig. 3c ).These data suggest that the predominant pathophysiological mechanism is heterozygous loss of function (haploinsufficiency).
We analyzed the phenotype associated with this new syndrome in the 26 mutation-positive individuals (Supplementary Table 2 ). Of 14 pediatric cases, 13 had craniosynostosis; in the 8 with accurate assessment by three-dimensional computed tomography (CT) of the skull, fusion affected the sagittal (n = 7), lambdoid (n = 5), coronal (n = 3) and metopic (n = 1) sutures ( Fig. 1d and Supplementary Table 3) , a pattern distinct from those observed in other monogenic types of craniosynostosis, in which the coronal suture is most commonly affected 13 . Seven of 12 probands had syndromic multiple-suture synostosis (Table 1) , representing a 13-fold enrichment compared to other diagnostic groups (P = 3 × 10 −5 , Fisher's exact test), but 3 subjects presented with single-suture synostosis of the sagittal (n = 2) or lambdoid (n = 1) sutures (Fig. 1e,f) . In half of the families, a diagnosis of Crouzon syndrome had been suggested because of exorbitism and midface hypoplasia (Fig. 1a,c ,g,h and Supplementary  Fig. 4) ; however, FGFR2 genetic testing 14, 15 was normal. Chiari type I malformations were diagnosed in four cases (Fig. 1i) ; pathologically raised intracranial pressure was documented in nine cases by invasive monitoring or skull radiology. Twelve pediatric cases (86%) had behavioral or learning problems, particularly affecting concentration and language acquisition (Supplementary Table 2) . Notably, despite the multiple-suture involvement, many affected individuals presented after infancy, and primary surgery was frequently delayed (Supplementary Fig. 5 ). Extracranial growth was normal, except for occasional mild shortening of the digits; no health problems of later onset were consistently found in carrier adults, in many of whom mild craniofacial signs or macrocephaly was the only clinical feature. npg l e t t e r s
No genotype-phenotype correlation was found. In 6 families, including 14 carriers of ERF mutation, we used three-dimensional scanning 16 to document the facial phenotype; this analysis showed that hypertelorism, shortening and/or vertical displacement of the nose and prominent orbits and forehead were consistently present but varied in severity (Fig. 1j, Supplementary Fig. 6 and Supplementary Movies 1-6). This newly recognized disorder, which we term ERF-related craniosynostosis, was identified in 5 of 402 (1.2%) of individuals requiring surgery for craniosynostosis in our extended Oxford cohort 13 (including children born between 1998 and 2006). A specific role for ERF was not previously suspected, either in the cranial sutures or in osteogenesis more generally. In the mouse, heterozygous loss of function of the orthologous gene (Erf +/− ) is not associated with any abnormality, whereas homozygous loss (Erf −/− ) causes severe placental defects resulting in death by embryonic day (E) 10.5 (ref. 17) . To explore the function of Erf during development, we engineered mice harboring a conditional allele (Erf loxP ) containing a selectable marker, PGKneo, located within intron 1, together with tandem loxP sites to enable Cre-mediated excision (Supplementary Fig. 7a) . RT-PCR analysis of Erf cDNA in dissected E16.5 mouse calvaria showed that, in Erf loxP/− compound heterozygotes, Erf transcription was reduced to 29% of the wild-type level (Fig. 3a) . This indicates that the Erf loxP allele is hypomorphic, probably because the intronic PGKneo cassette reduces the efficiency of transcript production. Both heterozygous (Erf loxP/+ ) and homozygous (Erf loxP/loxP ) conditional mice were grossly normal, but compound conditional and null heterozygotes (Erf loxP/− ) had domed heads that became apparent during the first 3-6 weeks of life. µCT scanning showed craniosynostosis affecting multiple calvarial sutures ( Fig. 3b-f and Supplementary Fig. 7b,c) . No other specific skeletal abnormalities were evident with Alizarin red and Alcian blue staining ( Supplementary Fig. 7d ). As in humans, the cranial sutures seem to be particularly sensitive to reduced Erf dosage, but the threshold level required for manifestation of the disease phenotype is lower in mice.
To explore the developmental origins of craniosynostosis in mice, we examined Erf expression and calvarial osteogenesis in E16.5 calvariae by whole-mount RNA in situ hybridization and RT-PCR. npg l e t t e r s
In wild-type animals, Erf was expressed along the osteogenic margins of the developing calvarial bones, in a similar distribution to that observed for the master osteogenic regulator Runx2 (Fig. 3g) ; in humans, haploinsufficiency for orthologous RUNX2 causes cleidocranial dysplasia associated with defective calvarial ossification, whereas complete duplications occur in craniosynostosis [18] [19] [20] [21] [22] Fig. 8a ). However, quantitation of transcripts in E16.5 calvariae showed modest (up to twofold) downregulation of multiple osteogenic markers in Erf loxP/− mutants compared to wild-type littermates, which was significant (P < 0.05, t test) in the Prkg2 and Serinc5 transcripts (Supplementary Fig. 8b ) 24 . At this stage of development, therefore, ossification seems to be mildly delayed in Erf loxP/− embryos. However, by postnatal day (P) 14, the coronal sutures of the Erf loxP/− but not of the Erf +/+ pups were variably fused (Supplementary Fig. 8c ). Further detailed analysis of intermediate time points will be necessary to document the timing of craniosynostosis in the Erf loxP/− mutants and to determine the relative contributions to this pathology of altered proliferation, differentiation and apoptosis 25 .
To gain insight into the nuclear targets of Erf, we employed chromatin immunoprecipitation (ChIP) in mouse embryonic fibroblasts (MEFs), using a previously characterized antibody specific to the C-terminal domain 3, 26 , combined with high-throughput sequencing (ChIP-seq). By comparing the enriched sequences from fibroblasts maintained without fetal calf serum (FCS) for 4 h (-FCS: inactive Erk1/2, nuclear Erf) to those from cells supplemented with FCS (+FCS: Erk1/2 phosphorylation and nuclear entry, consequent phosphorylation and nuclear export of Erf) 4,5,26 , we could identify the component of the ChIP-seq signal attributable to dynamic Erf binding (defined by a −FCS/+FCS ratio of >3). We divided signals of dynamic binding according to whether they occurred within 1 kb of a transcriptional start sites (TSS; putative promoter) or at greater distances (non-TSS; putative enhancer) (Fig. 3h and Supplementary Tables 4  and 5 ). MEME analysis 27 identified two major sequences enriched near TSSs (Supplementary Fig. 9a) , one corresponding to the ETS-binding consensus 12 and the other to the sequence bound by Ronin-Hcfc1 (ref. 28); these motifs are virtually identical to those in promoters bound by ETS1 (ref. 29) . In non-TSSs, which are believed to identify tissue-specific interactions of ETS factors 29 , the three most highly specific sequence motifs were 5′-TGANTCA-3′, 5′-TGTGG-3′ and 5′-TTCCT-3′, where N represents any nucleotide, corresponding to consensus motifs for AP-1, RUNX and ETS factors, respectively ( Fig. 3h and Supplementary Fig. 9a ). This suggests that Erf-binding sites frequently lie close to the binding sites for other transcription factors; corroborating this idea, enrichment of both AP-1 and RUNX sites was observed in ChIP-seq studies of other ETS proteins 29, 30 . The non-randomness of these associations was confirmed by showing that closely adjacent AP-1-ETS and RUNX-ETS sites exhibited polarity, consistent with interactions between pairs of transcription factors when binding DNA with specific orientation and separation (Supplementary Fig. 9b,c and Supplementary Tables 6 and 7) [29] [30] [31] [32] [33] . MetaCore analysis of non-TSS ChIP-seq targets npg l e t t e r s with a −FCS/+FCS ratio of >3 (n = 2,033) identified epithelialto-mesenchymal transition (EMT) as the process showing the greatest enrichment ( Supplementary Fig. 10) ; the RAS-MEK-ERK cascade and downstream AP-1 factors are located within the center of this network. Validating this analysis, ERF was recently identified experimentally as a negative regulator of EMT 34 . The identification of frequent RUNX-binding motifs within distal (non-TSS) Erf targets is of interest because Runx2 is a key dosagesensitive regulator of calvarial osteogenesis 18, 35 . The ChIP-seq data identified two sites of dynamic binding within introns of Runx2, which might reflect direct regulation of transcription (Supplementary Table 6 ). Alternatively, Erf may regulate osteogenesis by altering the balance of positive and negative regulatory complexes formed on DNA targets by Runx2 and other Ets proteins (such as Ets2) 36, 37 . We explored this hypothesis in two ways. First, we compared our Erf ChIP-seq data with a data set of 1,603 RUNX2-occupied regions in human prostate cancer cells 38 . There were 130 orthologous genes that were nearest to and had signals within 40 kb of a ChIP-seq peak in each of the data sets ( Fig. 4a and Supplementary Table 8) , a highly significant overlap (P = 4 × 10 −11 , hypergeometric test); moreover, Little et al. 38 identified enrichment of a hybrid ETS-RUNX binding motif very similar to the sequence (5′-GGATGTGG-3′) in our data set ( Supplementary  Fig. 9c ). Second, we examined the effects of ERF and RUNX2 on transactivation using a DNA-binding target containing this core sequence. Whereas RUNX2 alone elicited 1.6-fold upregulation of expression, this induction was suppressed by ERF, which lowered expression to below the basal level, similar to the effect of ERF added alone (Fig. 4b) , indicating antagonism by ERF of RUNX2-mediated transactivation in this model situation. Given that the ChIP-seq data showed potential interactions of Erf and Runx2 at numerous targets ( Fig. 4a and Supplementary Table 8) , further work will be required to identify critical factors in osteogenic dysregulation in the ERF or RUNX2 haploinsufficiency states.
Our genetic observations in humans and mice will focus renewed attention on the role of Ets factors in regulating osteogenesis, which although documented, is not well defined 36, 37, 39 . Direct Erk1/2-mediated phosphorylation was previously linked to stabilization and/or activation of Runx2 (refs. 40,41); we speculate that additional indirect control of Runx2 action by Erk1/2 (ref. 42) may be mediated by its control of Erf localization. Our data provide a pathway-based phenotypic link with FGFR2 mutations, as several individuals with ERF-related craniosynostosis were previously diagnosed with Crouzon syndrome (Supplementary Table 2) 14, 15 . The position of ERF downstream of the RAS-MEK-ERK cascade and the delayed onset of suture ossification associated with ERF haploinsufficiency (Supplementary Fig. 5 ) make ERF an attractive target for therapeutic modulation.
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METHodS
Methods and any associated references are available in the online version of the paper. Accession codes. Human ERF mRNA and genomic sequences are available as NCBI reference sequences NM_006494.2 and NC_000019.9, respectively. Mouse Erf mRNA sequence is available as NCBI reference sequence NM_010155.3. Human ETS DNA-binding protein sequences are available at UniProt under accession P50548 (ERF), P17947 (SPI1), P41212 (ETV6), P78545 (ELF3), P32519 (ELF1), O95238 (SPDEF), P43268 (ETV4), P19419 (ELK1), P14921 (ETS1), O00321 (ETV2), P11308 (ERG) and Q06546 (GABPα). Erf ChIP-seq data have been deposited at the Gene Expression Omnibus (GEO) under accession GSE42936.
oNLINE METHodS
Subjects. The clinical study was approved by Oxfordshire Research Ethics Committee B (reference C02.143) and Riverside Research Ethics Committee (reference 09/H0706/20). Written informed consent to obtain samples for genetics research was obtained from each child's parent or guardian. In most probands, the clinical diagnosis of craniosynostosis was confirmed by CT scanning, although some individuals had only skull radiography. Venous blood was obtained for DNA extraction and the preparation of lymphoblastoid cell lines. Fibroblast cultures were established from skin biopsies obtained from scalp incision during surgical intervention.
Exome sequencing and segregation analysis. We used an Agilent SureSelect Human All Exon kit (v.1; 38 Mb) to capture exonic DNA from a library prepared from 3 µg of DNA extracted from whole blood (subject IV-1 in family 1). Enriched DNA was sequenced on an Illumina Genome Analyzer IIx platform (51-bp paired-end reads), and the 3.1 Gb of sequence generated was mapped with Bowtie software 43 (hg19 genome), which gave an average coverage of 43-fold. Variants were called using SAMtools 44 (Supplementary Table 9 ). The proband and his brother and parents were genotyped using an Illumina HumanCytoSNP-12 BeadChip (300k). Chromosomal regions where the two affected boys shared the same maternal allele were identified and used to filter the exome data.
Mutation screening. Mutation analysis was performed by sequencing genomic PCR amplification products (BigDye Terminator v3.1, Applied Biosystems). Copy-number variation was analyzed by multiplex ligation-dependent probe amplification (MLPA). RNA was extracted from whole blood (PAXgene tubes, Qiagen) and lymphoblastoid cell lines (TRIzol, Invitrogen), and cDNA was synthesized with the RevertAid First-Strand cDNA kit (Thermo). The sequences of the primers for genomic and cDNA amplification and for MLPA and the details of all experimental conditions are provided in Supplementary Table 10 . cDNA numbering for ERF starts at the A of the ATG initiation codon (+1).
Three-dimensional facial imaging. Images were captured with a commercial photogrammetric device and manually landmarked, as were an additional 381 images of healthy controls for comparison. Dense surface model and signature analyses were undertaken as described 16, 45 . Face signatures were visualized as color-coded heat maps, derived from lateral, vertical and depth differences at 24,000 surface points compared to corresponding positions on the mean face of the matched controls.
Protein blots. Protein immunoblots were performed as described 4 . Cells or homogenized embryos were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, 50 mM Tris-(hydroxymethyl)-aminomethane, pH 8.0, 1 µg/ml aprotinin and 1 µg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM orthovanadate, 10 mM β-glycerophosphate) containing protease and phosphatase inhibitors. Equal amounts of protein were separated by discontinuous SDS electrophoresis and transferred onto nitrocellulose. ERF was detected with S17S rabbit polyclonal antibody to ERF (1:1,000 dilution), and ERK1/2 was detected with rabbit polyclonal antibody to ERK1/2 (Cell Signaling Technology, 9102; 1:1,000 dilution) in TBS with 0.1% Tween. Proteins were detected with horseradish peroxidase-conjugated secondary antibody to rabbit (Jackson ImmunoResearch; 1:5,000 dilution) and visualized by chemiluminescence. Autoradiographs were quantified using US National Institutes of Health (NIH) ImageJ software.
Promoter assays. Mutations identified in affected individuals were introduced into wild-type ERF cDNA by site-directed mutagenesis (QuikChange, Stratagene), cloned into pSG5-ERF and pSG424-ERF expression vectors 3 and sequence verified. The ability of wild-type and mutated ERF to repress transcriptional activity was determined in HeLa cells. The pGL333 reporter (with three copies of the GATA1 ets-binding site (ebs) and a minimal TK1 promoter), generated by transferring the corresponding promoter fragment from pBLCAT333 (ref. 46 ) into the pGL3-Basic vector (Promega), was used to determine repression on ebs-containing promoters. The pGLGal4 reporter (gal4 DNA-binding site and the SV40 promoter), generated by transferring the corresponding promoter fragment from SV40/GAL4 (ref.
3) into the pGL3-Basic vector, was used to assess ebs-independent repression.
For studies of RUNX2 and ERF interaction, the SfiI restriction fragment from pENTR223.1-RUNX2 plasmid (Open Biosystems), containing RUNX2 cDNA, was cloned into the EcoRI site of the pSG5 expression vector (Agilent Technologies) to generate pSG5-RUNX2. Double-stranded oligonucleotides encompassing the core Ets-Runx binding site (Supplementary Table 10 ) were cloned directionally between the NheI and BglII sites of the pGL3-Promoter luciferase reporter vector (Promega) to generate pGL3prom-D1. HeLa cells were transfected with the calcium phosphate method using 0.5 µg of pGL3prom-D1 reporter, 0.5 µg of pRSV-Gal for transfection efficiency control, 1 µg of pSG5-ERF and/or 1 µg of pSG5-RUNX2, and/or 0-2 µg of pSG5 to a total of 3 µg of DNA. All pairwise comparisons were significant (P < 0.01, t test), with the exception of ERF versus ERF and RUNX2. The Erf-targeting vector (Supplementary Fig. 7a ) was prepared by inserting a loxP sequence (ApaI site 16 bp 3′ of the Erf stop codon) and a PGKneo-loxP cassette (BstZ17I site 350 bp 5′ of Erf exon 2) within the 7.3-kb Erf genomic fragment 59A. loxP orientation was verified by sequencing, and the targeting fragment was inserted into pBSTK9 (ref. 47) . R1 ES cells were electroporated and selected as described 17 , and clones were screened by Southern blotting using a 2.2-kb BamHI-XbaI fragment (int-probe) for homologous recombination and absence of additional insertions. Positive clones were tested for the presence of the 3′ loxP site by PCR amplification using StopF2 and 5578R. Recombination after transfection with Cre recombinase-expressing plasmid was tested by PCR using Intr1-2 and 5578R ( Supplementary Fig. 7a and Supplementary Table 10) .
Generation of conditional
Chimeric mice were generated by microinjection of embryonic stem cell (ES) clones as described 17 . Cells from clone 89 were injected into 3.5-d post-conception C57BL/6 blastocysts and implanted into pseudopregnant CD1 females 48 . Male offspring with high levels of chimerism were mated to CBA×C57BL/6 females to produce Erf loxP/+ heterozygous mice. Erf loxP/− compound heterozygotes were obtained from an Erf +/− × Erf loxP/+ cross (Erf +/− animals were sourced either from a previously described knockout line 17 or by crossing Erf loxP/loxP mice with Meox2 tm1(cre)Sor /J mice 49 ). At birth, Erf loxP/− mice were on average ~18% lighter than their littermates, but they exhibited catch-up growth by 6 weeks of age.
Skeletal preparations and immunohistochemistry. Skeletons were fixed in 95% ethanol and stained overnight with Alcian blue (0.03% in 95% ethanol:20% acetic acid). After several washes with 95% ethanol, skeletons were rehydrated, treated with 2% KOH (12 h) and stained in 1% KOH containing 75 µg/ml Alizarin red S (24 h). Excess stain was removed in 1% KOH:20% glycerol, and, after washing in 0.2% KOH:20% glycerol, skeletons were stored in 50% glycerol.
The skulls of P14 mice were fixed overnight in 4% paraformaldehyde, decalcified using Calci-Clear (Raymond A Lamb) and embedded in paraffin. Immunohistochemistry was performed using a polyclonal antibody to RUNX2 (M-70, Santa Cruz Biotechnology) on 8-µm sections that were counterstained with hematoxylin.
mCT analyses. Specimens for µCT were scanned using a General Electric Locus SP µCT scanner (GE Healthcare). Specimens were immobilized using cotton gauze, scanned to produce voxel size volumes of 14-28 µm and characterized further by making three-dimensional isosurfaces, generated and measured using Microview (GE).
Whole-mount RNA in situ hybridization. Embryos were dissected and fixed in 4% paraformaldehyde and then dehydrated. In situ hybridization npg
